SecBot SecBot
Insider Cluster (2 insiders) ·Filed Apr 1, 2026

VIR

Vir Biotechnology, Inc.
BEARISH
Impact 6/10
Horizondays Processed7mo ago
Insider cluster: 2 insiders, $864K total
Actionable Insight ▼ Bearish

The CEO's material sale, over three times the size of the director's, raises questions about confidence in near-term prospects. Traders should monitor upcoming earnings or clinical trial updates for potential negative catalysts.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$9.02
T+0 close · Mar 31, 2026 · via day close
Latest settled
+15.08%
T+60 · $10.38
Vs SPY
+1.70%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 1 $9.02entry
  2. T+1 · 8mo ago +0.44%α +0.36% · $9.06
  3. T+5 · 7mo ago +8.98%α +5.21% · $9.83
  4. T+20 · 7mo ago +11.75%α +2.03% · $10.08
  5. T+60 · 5mo ago +15.08%α +1.70% · $10.38
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vir Biotechnology's CEO and a board director collectively sold $864K worth of shares in the past week, with the CEO accounting for 77% of the total volume. The sales occurred at market prices and represent open-market transactions, not automatic or non-cash dispositions.

Key Financial Metrics

Direction
selling
Total Value
$864.0K
Insiders
2

Key Facts

  • CEO Marianne De Backer sold 72,559 shares for $664,350 at $9.156 per share on April 6, 2026.
  • Director Vicki Sato sold 22,000 shares for $199,617 at $9.0735 per share on April 1, 2026.
  • Total insider selling cluster: $864K over a 7-day period.
  • All transactions were open-market sales (Form 4 code 'S'), indicating intentional divestment.

Financial Impact

$864K in insider sales over 7 days, representing 0.066% of the company's $1.3B market cap

insider ownershipmarket sentiment

Risk Factors

  • Insider selling, especially by the CEO, may signal reduced confidence in future performance or valuation.
  • Potential for negative market perception, particularly if no clear rationale (e.g., diversification) is disclosed.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-VIR-1775595151995

Track record

36 reports on VIR

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
  2. Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
  3. Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
  4. Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
  5. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
  6. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
  7. Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
  8. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
  10. Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens Wed (9h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 7, 2026